Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors

1. A recombinant polynucleotide encoding an alpha chain and/or a beta chain of a T cell receptor (TCR) selected from TCRs 19305DP, AL, KQ, PP, BB, KB, ST, JD, PB-P, PB-T, PB13.2, and 19305CD8, wherein the alpha chain and/or the beta chain comprises at least one of:

i) for 19305DP, an alpha chain comprising the sequence of SEQ ID NO:1 and/or a beta chain comprising the sequence of SEQ ID NO:2;

ii) for AL, an alpha chain comprising the sequence of SEQ ID NO:5 and/or a beta chain comprising the sequence of SEQ ID NO:6;

iii) for KQ, an alpha chain comprising the sequence of SEQ ID NO:9 and/or a beta chain comprising the sequence of SEQ ID NO:10;

iv) for PP, an alpha chain comprising the sequence of SEQ ID NO:13 and/or a beta chain comprising the sequence of SEQ ID NO:14;

v) for BB, an alpha chain comprising the sequence of SEQ ID NO:17 and/or a beta chain comprising the sequence of SEQ ID NO:18;

vi) for KB, an alpha chain comprising the sequence of SEQ ID NO:21 and/or a beta chain comprising the sequence of SEQ ID NO:22,

vii) for ST, an alpha chain comprising the sequence of SEQ ID NO:25 and/or a beta chain comprising the sequence of SEQ ID NO:26;

viii) for JD, an alpha chain comprising the sequence of SEQ ID NO:29 and/or a beta chain comprising the sequence of SEQ ID NO:30,

ix) for PB-P, an alpha chain comprising the sequence of SEQ ID NO:33 and/or a beta chain comprising the sequence of SEQ ID NO:34;

x) for PB-T, an alpha chain comprising the sequence of SEQ ID NO:37 and/or a beta chain comprising the sequence of SEQ ID NO:38,

xi) for PB13.2, an alpha chain comprising the sequence of SEQ ID NO:41 and/or a beta chain comprising the sequence of SEQ ID NO:42, and

xii) for 19305CD8, an alpha chain comprising the sequence of SEQ ID NO:45 and/or a beta chain comprising the sequence of SEQ ID NO:46.

2. The recombinant polynucleotide of claim 1 encoding the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and/or the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

3. The recombinant polynucleotide of claim 2 encoding the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

4. The recombinant polynucleotide of claim 1 , wherein the recombinant polynucleotide is present in an expression vector.

5. The recombinant polynucleotide of claim 4 , wherein the expression vector is present in a cell.

6. The recombinant polynucleotide of claim 5 , wherein the expression vector is present in a cell that is a CD4+ T cell or a CD8+ T cell.

7. The recombinant polynucleotide of claim 6 , wherein the expression vector encodes the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and/or the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

8. The recombinant polynucleotide of claim 6 , wherein the expression vector encodes the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

9. A method for therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer comprises cancer cells which express NY-ESO-1/LAGE-1 antigen, the method comprising administering to the individual modified human T cells comprising an expression vector of claim 4 .

10. The method of claim 9 , wherein the cancer cells are selected from bladder cancer cells, brain cancer cells, breast cancer cells, gastric cancer cells, esophageal cancer cells, head and neck cancer cells, hepatobiliary cancer cells, kidney cancer cells, ovary cancer cells, non-small cell lung cancer cells, myeloma, prostate cancer cells, sarcoma cells, testicular cancer cells, melanoma cells, or combinations thereof.

11. The method of claim 9 , comprising removing T cells from the individual prior to the administering, and modifying the T cells by introducing into the T cells the expression vector.

12. The method of claim 11 , wherein the expression vector encodes the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and/or the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

13. The method of claim 11 , wherein the expression vector encodes the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

14. The method of claim 11 , wherein the modified T cells in which the expression vector is present comprise CD4+ T cells, CD8+ T cells, or a combination thereof.

15. A library comprising a plurality of recombinant polynucleotides encoding the alpha chains and/or beta chain of T cell receptors (TCRs) of claim 1 .

16. The library of claim 15 , wherein the recombinant polynucleotides are present in expression vectors.

17. The library of claim 16 , wherein the recombinant polynucleotide encodes the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and/or the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

18. The library of claim 17 , wherein the recombinant polynucleotide encodes the 19305DP alpha chain comprising the sequence of SEQ ID NO:1 and the 19305DP beta chain comprising the sequence of SEQ ID NO:2.

19. The library of claim 17 , further comprising at least one additional recombinant polynucleotide encoding at least one TCR alpha chain and/or at least one TCR beta chain from AL, KQ, PP, BB, KB, ST, JD, PB-P, PB-T, PB13.2, 19305CD8, JM, 5B8, and SB95 TCRs.